Literature DB >> 10206124

Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood.

S Verhoef1, R van Diemen-Steenvoorde, W L Akkersdijk, N M Bax, Y Ariyurek, C J Hermans, O van Nieuwenhuizen, P G Nikkels, D Lindhout, D J Halley, K Lips, A M van den Ouweland.   

Abstract

UNLABELLED: A 12-year-old boy with tuberous sclerosis complex (TSC) presented with a large retroperitoneal tumour. Exploratory surgery revealed an infiltrative tumour originating from the pancreas, with local metastases to the lymph nodes. The histologal diagnosis was a malignant islet cell tumour. Retrospectively measured pancreatic hormone levels, however, were normal. A connection between the malignancy and TSC was demonstrated by loss of heterozygosity of the TSC2 gene in the tumour. The primary mutation Q478X in this patient was identified in exon 13 of the TSC2 gene on chromosome 16.
CONCLUSION: Pancreatic islet cell tumours have been mainly associated with multiple endocrine neoplasia syndrome type 1. In our case we demonstrate a direct relationship of this tumour to tuberous sclerosis complex, in the absence of further signs of multiple endocrine neoplasia syndrome type 1.

Entities:  

Mesh:

Year:  1999        PMID: 10206124     DOI: 10.1007/s004310051073

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  24 in total

1.  Complete inactivation of the TSC2 gene leads to formation of hamartomas.

Authors:  K S Au; A A Hebert; E S Roach; H Northrup
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Pancreatic tumors in children and young adults with tuberous sclerosis complex.

Authors:  Gonca Koc; Sam Sugimoto; Rachel Kuperman; Bamidele F Kammen; S Pinar Karakas
Journal:  Pediatr Radiol       Date:  2016-09-17

Review 3.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

4.  Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians.

Authors:  Jaya Sharma; Marvin Duque; M Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2013-11       Impact factor: 4.409

Review 5.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

Review 6.  Treatment of liver metastases in patients with digestive neuroendocrine tumors.

Authors:  Roberta Elisa Rossi; Sara Massironi; Matilde Pia Spampatti; Dario Conte; Clorinda Ciafardini; Federica Cavalcoli; Maddalena Peracchi
Journal:  J Gastrointest Surg       Date:  2012-07-25       Impact factor: 3.452

Review 7.  Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 8.  Rare and unusual endocrine cancer syndromes with mutated genes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 9.  Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway.

Authors:  Emmett V Schmidt; Michael J Ravitz; Li Chen; Mary Lynch
Journal:  Cell Cycle       Date:  2009-05-18       Impact factor: 4.534

Review 10.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.